Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neal Navani

Showing results (31-40 of 127) with videos related to

Pageof 13
Sort By:
Chest|November 5, 2018
The Accuracy of Clinical Staging of Stage I-IIIa Non-Small Cell Lung Cancer: An Analysis Based on Individual Participant DataNeal Navani, David J Fisher, Jayne F Tierney, et al.
Lung Cancer (Amsterdam, Netherlands)|June 11, 2025
Achieving equitable, timely and comprehensive biomarker testing for patients with NSCLCNeal Navani, Anna Sharman, Matthew Evison, et al.
Thorax|April 28, 2022
Ninety-day mortality following lung cancer surgery: outcomes from the English national clinical outcomes auditHelen Morgan, David Baldwin, Richard Hubbard, et al.
Thorax|November 25, 2010
The learning curve for EBUS-TBNANeal Navani, Matthew Nankivell, Parthiban Nadarajan, et al.
Respirology (Carlton, Vic.)|October 1, 2021
Variations in lung cancer care and outcomes: How best to identify and improve standards of care?Fraser Brims, Tracy Leong, Emily Stone, et al.
Thorax|December 28, 2019
Post-treatment survival difference between lobectomy and stereotactic ablative radiotherapy in stage I non-small cell lung cancer in EnglandAamir Khakwani, Susan Harden, Paul Beckett, et al.
Lung Cancer (Amsterdam, Netherlands)|September 13, 2022
Optimising tissue acquisition and the molecular testing pathway for patients with non-small cell lung cancer: A UK expert consensus statementNeal Navani, Rachel Butler, Salma Ibrahimo, et al.
British Journal of Cancer|August 24, 2016
How should performance in EBUS mediastinal staging in lung cancer be measured?Matthew Evison, Philip Crosbie, Neal Navani, et al.
Scientific Reports|October 28, 2024
Synthetic data for privacy-preserving clinical risk predictionZhaozhi Qian, Thomas Callender, Bogdan Cebere, et al.
Respirology (Carlton, Vic.)|January 30, 2014
High prevalence of malignancy in HIV-positive patients with mediastinal lymphadenopathy: a study in the era of antiretroviral therapyJoana Alçada, Magali N Taylor, Penny J Shaw, et al.
Pageof 13

Showing results (31-40 of 127) with videos related to

Sort By:
Pageof 13
Chest|November 5, 2018
The Accuracy of Clinical Staging of Stage I-IIIa Non-Small Cell Lung Cancer: An Analysis Based on Individual Participant DataNeal Navani, David J Fisher, Jayne F Tierney, et al.
Lung Cancer (Amsterdam, Netherlands)|June 11, 2025
Achieving equitable, timely and comprehensive biomarker testing for patients with NSCLCNeal Navani, Anna Sharman, Matthew Evison, et al.
Thorax|April 28, 2022
Ninety-day mortality following lung cancer surgery: outcomes from the English national clinical outcomes auditHelen Morgan, David Baldwin, Richard Hubbard, et al.
Thorax|November 25, 2010
The learning curve for EBUS-TBNANeal Navani, Matthew Nankivell, Parthiban Nadarajan, et al.
Respirology (Carlton, Vic.)|October 1, 2021
Variations in lung cancer care and outcomes: How best to identify and improve standards of care?Fraser Brims, Tracy Leong, Emily Stone, et al.
Thorax|December 28, 2019
Post-treatment survival difference between lobectomy and stereotactic ablative radiotherapy in stage I non-small cell lung cancer in EnglandAamir Khakwani, Susan Harden, Paul Beckett, et al.
Lung Cancer (Amsterdam, Netherlands)|September 13, 2022
Optimising tissue acquisition and the molecular testing pathway for patients with non-small cell lung cancer: A UK expert consensus statementNeal Navani, Rachel Butler, Salma Ibrahimo, et al.
British Journal of Cancer|August 24, 2016
How should performance in EBUS mediastinal staging in lung cancer be measured?Matthew Evison, Philip Crosbie, Neal Navani, et al.
Scientific Reports|October 28, 2024
Synthetic data for privacy-preserving clinical risk predictionZhaozhi Qian, Thomas Callender, Bogdan Cebere, et al.
Respirology (Carlton, Vic.)|January 30, 2014
High prevalence of malignancy in HIV-positive patients with mediastinal lymphadenopathy: a study in the era of antiretroviral therapyJoana Alçada, Magali N Taylor, Penny J Shaw, et al.
Pageof 13